Stock Ratings / Health Care / BLRX / earnings

PHIO (42) GDTC (54) TPST (44) BFRG (40) ⌘ Pro Terminal →

BioLineRx Ltd. (BLRX) Next Earnings Date & Expected ±12.5% Move

$2.02 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BioLineRx Ltd. (BLRX) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $10.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLRX)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.25 Expected Swing

MODEL EARNINGS SETUP GAUGE

BLRX Quantitative Pre-Earnings Setup: 60/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (60/100)Model Risk Weight (40/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating BLRX & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on BLRX
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BLRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.55%▼ DESCENDING CHANNEL

2026-10-30O $1.95H $2.02L $1.94C $2.02VOL 8.8K

RES: $2.59SUP: $1.78SMA50: $2.39SMA200: $2.74

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BLRX Butterfly Map → + Track BLRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BLRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BLRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BLRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLRX)

Health Care Rank #207 of 1016 ⚔️ PHIO vs BLRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BLRX vs. PHIO, GDTC, TPST, BFRG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioLineRx Ltd. (BLRX) ranks #207 by composite RQD confidence (60/100, grade C-) and #895 by equity capitalization ($10.1M). Within this direct 5-issuer industry benchmark cohort, BLRX leads on earnings valuation at N/A trailing P/E, while PHIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BLRX currently leads its immediate peer cohort in composite quantitative strength at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BLRX ACTIVE BioLineRx Ltd.	C-	60/100	—	—	—	+1.00%	$10.1M	Benchmark Subject
PHIO Phio Pharmaceuticals Corp.	D-	42/100	—	—	-35.0%	-5.91%	$10.0M	/phio-vs-blrx →
GDTC CytoMed Therapeutics Limited	D+	54/100	—	—	—	-3.68%	$10.7M	/gdtc-vs-blrx →
TPST Tempest Therapeutics Inc.	D	44/100	—	—	-35.0%	-1.24%	$10.7M	/tpst-vs-blrx →
BFRG Bullfrog AI Holdings Inc.	D-	40/100	—	18.8%	-35.0%	+3.88%	$9.4M	/bfrg-vs-blrx →

2. BLRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BioLineRx Ltd. (BLRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $10.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BLRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BioLineRx Ltd. (NASDAQ: BLRX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $2.02 (+1.00% 1D, market cap $10.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BLRX ranks #207 in composite RQD confidence.

How does BLRX compare to PHIO and GDTC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BLRX carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PHIO (Phio Pharmaceuticals Corp.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $10.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $10.7M). Among the 5-stock peer group, BLRX leads on earnings multiple (N/A) while PHIO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLRX?

For BioLineRx Ltd. (BLRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #207 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLRX trading relative to its 50-day, 200-day, and 52-week technical levels?

BLRX last traded at $2.02 (+1.00% on volume of 4,149 shares), positioning the stock -15.48% below its 50-day simple moving average ($2.39) and -26.28% below its 200-day simple moving average ($2.74). Across its 52-week range of $1.94 to $3.95, BLRX sits at the 4.0% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.77 to $2.27).